Merit Medical Systems, Inc. (MMSI)
| Market Cap | 3.73B -36.1% |
| Revenue (ttm) | 1.54B +11.1% |
| Net Income | 139.34M +14.0% |
| EPS | 2.32 +13.8% |
| Shares Out | 59.65M |
| PE Ratio | 26.94 |
| Forward PE | 15.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 919,496 |
| Open | 64.67 |
| Previous Close | 64.52 |
| Day's Range | 62.09 - 65.00 |
| 52-Week Range | 59.74 - 97.18 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 90.64 (+44.98%) |
| Earnings Date | Apr 30, 2026 |
About MMSI
Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States, China, Japan, Germany, France, the United Kingdom, and internationally. It operates through two segments, Cardiovascular and Endoscopy. The company offers micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention products comprising angiography, drainage, delivery systems, and embolotherapy products; oncology produc... [Read more]
Financial Performance
In 2025, Merit Medical Systems's revenue was $1.52 billion, an increase of 11.75% compared to the previous year's $1.36 billion. Earnings were $128.49 million, an increase of 6.76%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for MMSI stock is "Buy." The 12-month stock price target is $90.64, which is an increase of 44.98% from the latest price.
News
Merit Medical Shareholders Elect Scott R. Ward to Board of Directors
SOUTH JORDAN, Utah, May 19, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that shareholders ...
Merit Medical Systems Transcript: AGM 2026
Shareholders approved all proposals, including director elections and compensation plans, and welcomed a new CEO and director. The company reported record financial results, continued innovation, and outlined ongoing strategic growth initiatives.
Merit Medical Systems Transcript: Bank of America Global Healthcare Conference 2026
Revised summary: Leadership emphasized a shift to platform-based management, aligning reporting with operations and focusing on scaling through people, process, and innovation. Growth is driven by foundational and therapeutic platforms, with acquisitions expanding offerings. Margin expansion and diversified growth remain priorities, with ongoing strategic planning and prudent M&A.
Merit Medical to Participate in the Bank of America Healthcare Conference
SOUTH JORDAN, Utah, May 08, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced that Merit managem...
Merit Medical price target lowered to $83 from $92 at Baird
Baird analyst David Rescott lowered the firm’s price target on Merit Medical (MMSI) to $83 from $92 and keeps an Outperform rating on the shares. The firm updated its model…
Merit Medical price target lowered to $77 from $95 at JPMorgan
JPMorgan lowered the firm’s price target on Merit Medical (MMSI) to $77 from $95 and keeps an Overweight rating on the shares.
Merit Medical price target lowered to $90 from $101 at Needham
Needham lowered the firm’s price target on Merit Medical (MMSI) to $90 from $101 and keeps a Buy rating on the shares after it is better than expected Q1 earnings…
Merit Medical price target lowered to $83 from $101 at Raymond James
Raymond James lowered the firm’s price target on Merit Medical (MMSI) to $83 from $101 and keeps an Outperform rating on the shares. Merit Medical delivered a solid Q1 with…
Merit Medical price target lowered to $80 from $100 at BofA
BofA analyst Craig Bijou lowered the firm’s price target on Merit Medical (MMSI) to $80 from $100 and keeps a Neutral rating on the shares. While the Q1 beat did…
Merit Medical price target lowered to $85 from $90 at Canaccord
Canaccord lowered the firm’s price target on Merit Medical (MMSI) to $85 from $90 and keeps a Buy rating on the shares. The firm said they reported a Q1 beat…
Merit Medical Systems Earnings Call Transcript: Q1 2026
Q1 2026 delivered strong revenue and profit growth, exceeding expectations, with record non-GAAP operating margin and robust free cash flow. Strategic acquisitions, notably View Point Medical, expanded the oncology platform and future growth prospects.
Merit Medical Systems Earnings release: Q1 2026
Merit Medical Systems released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Merit Medical Systems Quarterly report: Q1 2026
Merit Medical Systems has published its Q1 2026 quarterly earnings report on April 30, 2026.
Merit Medical Systems Slides: Q1 2026
Merit Medical Systems has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Merit Medical Reports First Quarter 2026 Results and Updates Full-Year Guidance
Financial Highlights† Reported revenue of $381.9 million, up 7% Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively Constant currency revenue, organic* inc...
Merit Medical price target lowered to $107 from $109 at Barrington
Barrington analyst Michael Petusky lowered the firm’s price target on Merit Medical (MMSI) to $107 from $109 and keeps an Outperform rating on the shares, citing the short-term dilutive impact…
Merit Medical price target lowered to $96 from $106 at Piper Sandler
Piper Sandler lowered the firm’s price target on Merit Medical (MMSI) to $96 from $106 and keeps an Overweight rating on the shares. The firm says it is recasting its…
Merit Medical price target lowered to $100 from $107 at BTIG
BTIG analyst Sam Eiber lowered the firm’s price target on Merit Medical (MMSI) to $100 from $107 and keeps a Buy rating on the shares as part of a broader…
Merit Medical price target lowered to $90 from $99 at Canaccord
Canaccord lowered the firm’s price target on Merit Medical (MMSI) to $90 from $99 and keeps a Buy rating on the shares. The fim updated its model to reflect the…
Merit Medical acquires View Point Medical for $140M
Merit Medical (MMSI) announced it has acquired View Point Medical. Through a merger transaction, View Point is now a wholly-owned subsidiary of Merit. View Point, located in Carlsbad, California, manu...
Merit Medical Systems Proxy statement: Proxy filing
Merit Medical Systems filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Merit Medical Systems Proxy statement: Proxy filing
Merit Medical Systems filed a proxy statement on March 31, 2026, providing details for shareholder voting and corporate governance matters.
Medtronic, Merit Medical enter pact to offer new, FDA-cleared ViaVerte system
Medtronic (MDT) announced that it has entered into a distribution agreement with Merit Medical Systems (MMSI), to offer FDA-cleared ViaVerte, a minimally invasive and implant free basivertebral nerve ...
Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain
Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Me...
Merit Medical launches Resilience TTS Esophageal Stent
Merit Medical (MMSI) Systems announced the US commercial release of the Resilience Through-the-Scope Esophageal Stent. The Resilience stent is the newest product in Merit’s Endoscopy portfolio, joinin...